The extensive timeline to develop a drug is due to a multitude of formulation challenges that formulation experts face. When it comes to solving these challenges, there have been significant advancements in drug development techniques to counter them, including bioavailability, stability, efficacy, manufacturability, and safety. This e-book explores tools and processes that can further help provide a solution.
Salmon Calcitonin, a peptide with poor oral bioavailability, was assessed for its oral delivery potential using parallel screening with two different technologies targeting duodenal and sublingual biological barriers respectively. Lipid formulations and lyophilized tablet formulations were developed in parallel. The optimal formulation and dose form was identified, which increased the bioavailability of Salmon Calcitonin by more than 20 times.
Pharmacokinetic and pharmacodynamic differences can make drug development challenging for very young patients. One can think of pediatric medicines as one of the last uncharted frontiers in patient-centric drug development. Read about the many improvements in pediatric drug development that have occurred during the last 15 years and what is being done to continue moving forward.
Trio Medicines Ltd is a London-based pharmaceutical company developing treatments for unmet medical needs, including rare diseases, with the aim of improving the health and quality of life of patients worldwide. Learn how a structured 3-step approach helped Trio overcome the challenges of molecular characterization and a limited budget.